Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Larch resin + pennywort is a botanical combination therapy under development by the Verein für Krebsforschung (VfK) for the treatment of oncological wounds (open cancerous tumors) and poorly healing wounds. The formulation contains extracts from larch resin (*Larix decidua*) and pennywort (*Lysimachia nummularia*). It is being developed in two topical dosage forms: a cream and an emulsion spray. The therapy is intended to promote wound healing in complex clinical settings, such as malignant cutaneous lesions, though its specific molecular mechanism of action has not been detailed. It is currently in the preclinical stage of pharmaceutical development and formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on larch resin + pennywort.